HALOPERIDOL DECANOATE

SynDRA canonical compound SYN0023327 — structure-anchored drug synonym record

Clinical phase	Launched
Approval status	Approved · Rx/OTC
Primary target(s)	CYP1A1 \| CYP1A2 \| CYP2D6 \| CYP3A4 \| CYP3A7 \| DRD2 \| DRD3 \| DRD4 \| HTR2A
Mechanism of action	psychoactive drug
Indication	schizophrenia
Disease area	neurology/psychiatry

All known targets

DRD2
DRD3
DRD4
HTR2A
CYP1A1
CYP1A2
CYP2D6
CYP3A4
CYP3A7
DRD1
HTR1A
HTR1D

Mechanisms of action (all sources)

HTR2A ANTAGONIST
Serotonin 2a (5-HT2a) receptor antagonist
DRD2 INVERSE AGONIST
D2-like dopamine receptor inverse agonist
DRD3 INVERSE AGONIST
DRD4 INVERSE AGONIST
Dopamine receptor antagonist
HTR1A ANTAGONIST
HTR1D ANTAGONIST
HTR2B ANTAGONIST
HTR7 ANTAGONIST
DRD1 ANTAGONIST

Bioactivity evidence (ChEMBL activities table — not curator-asserted)

HDAC6

Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)

KCNK2

Drug classes

Antipsychotic Agents
Central Nervous System Agents
Central Nervous System Depressants
Psychotropic Drugs
Tranquilizing Agents
Anti-Dyskinesia Agents
Antiemetics
Dopamine Agents
Dopamine Antagonists
Gastrointestinal Agents
Neurotransmitter Agents
Peripheral Nervous System Agents

ATC classes

N05A · ANTIPSYCHOTICS

Cross-references

PubChem CID: 52919
ChEMBL: CHEMBL1200986
ChEBI: CHEBI:31664
KEGG: D01898
RxNorm: 26420
Wikipedia: Haloperidol_decanoate

Synonyms

Reported adverse events

Dystonia
Agranulocytosis
Neuroleptic malignant syndrome
Tachycardia
Tardive dyskinesia
Insomnia
Dyskinesia
Dry mouth
Laryngospasm
Cataract
Akinesia
Jaundice

Look up HALOPERIDOL DECANOATE in the interactive SynDRA portal →